CertainT-1CER-1236 for Acute Myeloid Leukemia Patients

This clinical trial is focused on testing a new treatment called CER-1236 for patients with a type of blood cancer known as acute myeloid leukemia (AML), specifically those whose cancer has returned or is hard to treat. The study is particularly interested in patients who have measurable residual disease or a genetic mutation called TP53mut. The goal is to see if CER-1236, which is a special type of cell therapy that targets a specific protein involved in the cancer, is safe and effective. This research is crucial because current treatment options for these patients are limited, and finding new, effective therapies can significantly improve outcomes. The study is conducted in two parts. In the first part, different doses of CER-1236 are given to patients to determine which dose is safe and should be used in the second part. The treatment involves using the patient's own modified immune cells, which are then reintroduced to their body to attack the cancer cells. The study checks how safe the treatment is and whether it works to control the cancer. This involves closely monitoring participants for any side effects and assessing the impact of the therapy on their disease. This approach helps ensure that the treatment is not only effective but also safe for the patients involved.